Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innate Pharma (DE:IDDA)
FRANKFURT:IDDA
Innate Pharma (IDDA) Stock Price & Analysis
0 Followers
IDDA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.87 - €3.10
Previous Close€2.08
Volume0.00
Average Volume (3M)N/A
Market Cap
€182.70M
Enterprise Value€136.57M
Total Cash (Recent Filing)€92.46M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)N/A
Beta0.33
Next Earnings
Sep 12, 2024EPS Estimate
-€0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,453,282
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.84
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.72Price Target Upside415.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Innate Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAssets from Innate Pharma's ANKET and ADC franchises hold promise of definitive early-phase clinical catalysts and growth upside.
Research And DevelopmentPreclinical data with IPH45 shows promise as an effective ADC, with a high drug-antibody-ratio (DAR) of 8, suggesting a potent therapeutic capability.
Strategic OwnershipInnate retains ownership of the oncology ADCs and a CD20-targeted ANKET, indicating a different risk profile with potentially higher rewards.
Bears Say
Clinical Trial SetbackInnate reported discontinuation of the monotherapy arm of the KILT Ph 2 trial, which did not meet the company's internal expectations.
Efficacy IssuesThe drug failed to achieve an internal threshold for meaningful clinical activity.
Safety ConcernsThere is the possibility of off-target toxicity, with comprehensive safety data being awaited.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.14% Other Institutional Investors
99.86% Public Companies and
Individual Investors
IDDA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was €1.87 and its highest was €3.10 in the past 12 months.
What is Innate Pharma’s market cap?
Currently, no data Available
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 12, 2024 which is in 137 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 21, 2024. The company reported -€0.121 earnings per share for the quarter, beating the consensus estimate of -€0.407 by €0.286.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -€0.36.
How many shares outstanding does Innate Pharma have?
Currently, no data Available
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -€0.121 in its last earnings report, beating expectations of -€0.407. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in DE:IDDA
---
Innate Pharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.98%
12-Months-Change
Fundamentals
Return on Equity
-14.23%
Trailing 12-Months
Asset Growth
-8.28%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
---
IDDA Company Deck
---
IDDA Earnings Call
Q4 2024
0:00 / 0:00
---
IDDA Stock 12 Months Forecast
Average Price Target
€10.72
▲(415.40% Upside)
Technical Analysis
Innate Pharma
―
Eiger Biopharmaceuticals
―
Corvus Pharmaceuticals
―
MacroGenics
―
Nektar Therapeutics
―
Best Analysts Covering IDDA
1 Year
1 Year Success Rate
5/19 ratings generated profit
1 Year Average Return
-12.89%
reiterated a buy rating 17 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -12.89% per trade.
---